Esmolol CRI

Selective β1-adrenergic blocker with ultra-short half-life (~9 minutes). Metabolized by erythrocyte esterases, independent of hepatic or renal function, and safe in compromise of either. Onset 1–2 min IV; full effect within 5–10 min; offset 10–20 min after stopping, making it among the most titratable IV cardioactive drugs available. β1-selectivity is preserved at low-mid doses but is lost at higher rates (becomes nonselective with β2 effects on airway smooth muscle).

Open calculator →

Clinical background

Esmolol is an ultra-short-acting cardioselective (β₁) beta-adrenergic antagonist used in vet ICU for acute rate control in supraventricular tachyarrhythmia, ventricular tachyarrhythmia where adrenergic drive contributes to the rhythm, and management of catecholamine-driven hypertension (anaphylaxis with epinephrine on board, pheochromocytoma after α-blockade, severe hyperthyroid crisis). The clinical pivot is duration: esmolol’s half-life is 9–10 minutes, so an unwanted hemodynamic effect washes out within 20–30 minutes of stopping the infusion. This makes esmolol the safest β-blocker to test in a patient where the clinical risk of a longer-acting agent (propranolol, atenolol) feels too high to commit to.

Pharmacology

Cardioselective β₁ antagonist with no intrinsic sympathomimetic activity and no membrane-stabilizing effect at therapeutic doses. The receptor profile produces:

• Negative chronotropy: slows the sinus rate and AV-nodal conduction
• Negative inotropy: modestly reduces contractility
• Negative dromotropy: prolongs AV-nodal refractoriness, which is the mechanism for SVT rate control
• No significant α activity: vasoconstriction is not produced or blocked
• No significant β₂ activity at therapeutic doses: bronchoconstriction is less common than with non-selective beta-blockers, but selectivity is dose-dependent and erodes above 200 µg/kg/min

Onset is within 1–2 minutes IV; full effect develops within 5 minutes after a loading dose. Esmolol is hydrolyzed by red blood cell esterases (not plasma cholinesterase, not hepatic enzymes), so clearance is independent of liver or kidney function. This pharmacokinetic feature is genuinely useful: in a patient with uncertain hepatic or renal function who needs beta-blockade, esmolol is a more predictable choice than metoprolol or propranolol.

The metabolite is a methanol derivative that is inactive at therapeutic doses; methanol accumulation has been described only at supratherapeutic doses and in humans with prolonged infusions, not at clinically relevant rates in vet patients.

Indications

Primary use cases:

• Acute supraventricular tachycardia (SVT) rate control, including atrial fibrillation, atrial tachycardia, and AV-nodal reentrant tachycardia. Esmolol slows AV-nodal conduction and reduces ventricular response rate. Useful when the rhythm itself is not the priority but the ventricular rate is compromising hemodynamics.
• Catecholamine-driven hypertension and tachyarrhythmia. Pheochromocytoma management after α-blockade is on board, severe hyperthyroid crisis, anaphylaxis-related hypertension when concurrent epinephrine has produced excessive cardiovascular response. Always after α-blockade in pheochromocytoma; the consequences of unopposed α-mediated vasoconstriction can be severe.
• Ventricular tachyarrhythmia with adrenergic drive. Adjunctive use in patients with sustained VT or frequent VPCs where increased sympathetic tone is contributing. Used alongside, not instead of, class IB antiarrhythmics in most cases.
• Tachycardia during anesthesia that is not responding to lightening the plane and fluid optimization, where rate control would meaningfully improve diastolic filling and stroke volume. Less common; usually only in patients with known cardiac disease.

Esmolol is not for chronic outpatient rate control (the half-life is far too short for that role). It is the bridge drug while the diagnosis is clarified and a longer-acting agent is being chosen.

Dosing

• Dogs and cats, rate control CRI: 25–200 µg/kg/min, titrated against rate and rhythm.
• Initial maintenance rate: 25–50 µg/kg/min after a loading dose.
• Caution above: 150 µg/kg/min, where β₁ selectivity erodes and β₂ blockade can produce bronchospasm in predisposed patients. Reassess indication before pushing higher.
• Loading dose: 50–500 µg/kg IV over 1 minute before starting the CRI. The wide range reflects the variable clinical scenarios; 250 µg/kg is a typical starting load in a hemodynamically stable patient with SVT and good baseline cardiac function.
• The loading dose can be repeated every 4–5 minutes if rate control is inadequate, while titrating the CRI upward in parallel.

The combination of a loading bolus and a CRI is the standard approach. A bolus alone wears off too quickly (15–20 minutes); a CRI alone takes longer to reach effect than the rhythm usually allows. Both together produce rate control within 5 minutes that is sustained as long as the infusion runs.

Cat dosing uses the same range as dogs. Cats with HCM may be particularly sensitive to negative inotropy; in obstructive HCM (dynamic LVOT obstruction) beta-blockade is generally beneficial because it reduces the contractility that drives the obstruction. In non-obstructive HCM with poor systolic function, esmolol’s negative inotropy can be problematic.

Administration

Stock concentration in the US is 10 mg/mL (premixed 100 mL bag Brevibloc and equivalents), often supplied as a single-dose premix that does not require dilution. A 2500 mg in 250 mL premix bag is also available. For very small patients the InfusionFox calculator suggests further dilution to 5 mg/mL or 2 mg/mL to keep the pump rate above 2 mL/hr.

Compatibility is broad. Esmolol can run through a peripheral line, although a central line is preferred for sustained infusions running longer than several hours. The premix is stable at room temperature for 24 hours after the seal is broken.

Avoid concurrent administration in the same line with sodium bicarbonate, diazepam (which is propylene-glycol-based and may precipitate), and amphotericin B. Most other ICU drugs Y-site fine.

Drug interactions

• Calcium channel blockers, particularly the non-dihydropyridines (diltiazem, verapamil), produce additive AV-nodal blockade and negative inotropy. The combination can precipitate complete heart block or cardiogenic shock; co-administration is generally avoided. If both are clinically needed (rate-control resistant SVT), they are titrated in sequence with continuous ECG and BP monitoring, not started simultaneously.
• α-adrenergic agonists (epinephrine, phenylephrine, dopamine at higher doses) can produce unopposed α-mediated vasoconstriction during beta-blockade, with severe hypertension. Most clinically relevant in the pheochromocytoma setting, where α-blockade must precede esmolol use.
• Digoxin has additive AV-nodal effect; rate may slow more than expected. Watch for increased AV-block grade.
• Insulin: beta-blockade can mask hypoglycemia signs (tachycardia, tremor) in diabetic patients. The clinical implication is short-term, given esmolol’s brief duration, but worth knowing.
• Inhalant anesthetics produce additive negative inotropy and hypotension. Reduce inhalant concentration when possible during esmolol use.

Adverse effects

• Bradycardia is the most common dose-limiting effect. Watch for hemodynamically significant slowing rather than the modest rate reduction that is the goal of therapy.
• Hypotension, primarily through negative inotropy and reduced sympathetic outflow. Common in volume-depleted patients or those with limited cardiac reserve.
• AV block (any grade); usually first-degree at therapeutic doses, occasionally higher grades, particularly with concurrent calcium channel blockers or digoxin.
• Bronchospasm in patients with reactive airway disease, more likely at infusion rates above 150 µg/kg/min where β₁ selectivity erodes.
• Heart failure decompensation in patients with already-compromised systolic function. Negative inotropy can produce acute decompensation; reassess clinical status frequently in patients with reduced ejection fraction.
• Infusion site irritation at higher concentrations; the premixed 10 mg/mL formulation is well tolerated, but extravasation of higher concentrations can produce local injury.

Monitoring

• Continuous ECG for rate, rhythm, AV-block grade, and ST-segment changes. The combination of dropping rate and lengthening PR interval is the expected response; lengthening QRS or new arrhythmia is not.
• Continuous or frequent blood pressure, particularly during loading and the first 30 minutes of CRI. Hypotension is the most likely acute problem.
• Respiratory rate and effort in patients with reactive airway disease or those running at higher CRI rates. Watch for bronchospasm signs.
• Mental status as a perfusion marker, particularly if MAP is borderline. Cats are good at masking declining cardiac output until they are markedly compromised.
• Glucose in diabetic patients; the brief duration of beta-blockade limits the masked-hypoglycemia concern but does not eliminate it.

Weaning

For brief infusions managing acute rate control, esmolol can usually be stopped abruptly once the underlying driver (catecholamine surge, anesthetic-related tachycardia, transitioning to a longer-acting agent) has resolved. The short half-life means rebound is unlikely to be clinically problematic.

For prolonged infusions (multi-day), wean by 25–50% every 30–60 minutes. The principal concern is unmasking the underlying rhythm or hypertensive drive that prompted starting esmolol in the first place. Transition to oral atenolol or another sustained-action beta-blocker if rate control is needed beyond the duration of the IV infusion.

Sources

• Plumb’s Veterinary Drugs, esmolol monograph (current edition).
• Wright KN, Mehdirad AA, Giacomini K, Giacomini J, Lerman BB. Acceptability of esmolol for elective ablation. Pacing Clin Electrophysiol. 1998;21(11 Pt 2):2380–2381. (Foundational human PK/PD reference for the RBC-esterase metabolism property that informs the vet adoption.)
• Côté E, MacDonald KA, Meurs KM, Sleeper MM, eds. Feline Cardiology. Wiley-Blackwell; 2011. (Beta-blocker use in feline HCM, distinction between obstructive and non-obstructive forms.)
• Kittleson MD, Côté E. Drug therapy of heart failure. In: Ettinger SJ, Feldman EC, Côté E, eds. Textbook of Veterinary Internal Medicine. 8th ed. Elsevier; 2017. (Beta-blocker class effects and selection criteria in vet cardiology.)